Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Published:2020-08-13 Issue: Volume: Page:
ISSN:
Container-title:Bioinformatics, Convergence Science, and Systems Biology
language:
Short-container-title:

Author:

Bendell Johanna C.,Bedard Philippe,Bang Yung-Jue,LoRusso Patricia,Hodi Stephen,Gordon Michael,D'Angelo Sandra,D'Angelo Sandra,Desai Jayesh,Garralda Elena,Italiano Antoine,Ahn Myung-Ju,Cervantes Andres,Wainberg Zev,Calvo Emiliano,Gil-Martin Marta,Martinez-Garcia Maria,Bahleda Rastilav,Cassier Philippe,Delord Jean-Pierre,Prawira Amy,Melero Ignacio,Emens Leisha,Romano Emanuela,Miller Karen,Hsieh Robert W.,Xue Cloris,Morrissey Kari,Twomey Patrick,Gash Kelly,Patil Namrata S.,Grogan Jane,Meng Raymond,Cho Byoung,Kim Tae Won

Publisher

American Association for Cancer Research

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells;Nature;2024-02-28

2. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer;Journal of Clinical Oncology;2024-01-20

3. Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors;Cancer Chemotherapy and Pharmacology;2024-01-11

4. Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox;Current Oncology;2023-12-23

5. The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?;Cancers;2023-12-08